PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS

Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune r...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Iñigo-Marco, Ignacio, Díez-Valle, Ricardo, Garcia-Moure, Marc, Patiño-García, Ana, González Huarriz, Marisol, Jones, Chris, Gomez-Manzano, Candelaria, Fueyo, Juan, Alonso, Marta M, Tejada, Sonia
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Late Breaking Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6873625/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz219.1197
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items